pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 3·1 min read
save

Alnylam to pay $30M upfront to AI startup Inceptive in RNA R&D deal

Alnylam Pharmaceuticals announced its first discovery-focused AI deal Wednesday, tapping a Silicon Valley biotech startup to see if AI can boost its R&D efforts. Alnylam and Inceptive signed a collaboration combining the Cambridge, MA-based company's ...

Jun 3, 2026·read at Endpoints ↗

June 3, 2026 04:45 PM EDT DealsR&DAI Al­ny­lam signs its first AI dis­cov­ery deal with RNA spe­cial­ist In­cep­tive Andrew Dunn Senior Biopharma Correspondent Al­ny­lam Phar­ma­ceu­ti­cals an­nounced its first dis­cov­ery-fo­cused AI deal Wednes­day, tap­ping a Sil­i­con Val­ley biotech start­up to see if AI can boost its R&D ef­forts. Al­ny­lam … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
83 words · retrieved Jun 3
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2h agoSummit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trialEndpoints
  • 4h agoSuperluminal secures $60M for Phase 1 of genetic obesity drugEndpoints
  • 4h agoGSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfrontEndpoints
  • 12h agoUltragenyx’s Angelman therapy fails Phase 3 trial in setback for company and patientsEndpoints
  • 18h agoFDA leaders project enhanced scrutiny of foreign dataEndpoints